Drug Database · Clinicians

Methylprednisolone

Brands (61) Solu-Medrol, Methyden, Empred-40…Show all

Corticosteroid (glucocorticoid); Glucocorticoid; and others PH FDA category

Rx · Prescription drug85 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 95ec0e75-6b5d-4320-8f23-3d6229216ca8, version date October 27, 2026 (Depo-Medrol · Sportpharm LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the…
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions.

Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis.

Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia.

Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Cerebral edema associated with primary or metastatic brain tumor or craniotomy.

Ophthalmic Diseases: Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.

Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

B. For Intra-articular Or Soft Tissue Administration (see WARNINGS) DEPO-MEDROL is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.

C. For Intralesional Administration DEPO-MEDROL is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum.

DEPO-MEDROL also may be useful in cystic tumors of an aponeurosis or tendon (ganglia).

Contraindications

CONTRAINDICATIONS DEPO-MEDROL is contraindicated in patients with known hypersensitivity to the product and its constituents. Intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura. DEPO-MEDROL is contraindicated for intrathecal administration. This formulation of methylprednisolone acetate has been associated with reports of severe medical events when administered by this route.

DEPO-MEDROL is contraindicated in systemic fungal infections, except when administered as an intra-articular injection for localized joint conditions (see WARNINGS: Immunosuppression and Increased Risk of Infection, Fungal Infections).

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Because of possible physical incompatibilities, DEPO-MEDROL Sterile Aqueous Suspension should not be diluted or mixed with other solutions. The initial dosage of parenterally administered DEPO-MEDROL will vary from 4 to 120 mg, depending on the specific disease entity being treated. However, in certain overwhelming, acute, life-threatening situations, administration in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages.

It Should Be Emphasized that Dosage Requirements Are Variable and Must Be Individualized on the Basis of the Disease Under Treatment and the Response of the Patient. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached.

Situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient’s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation, it may be necessary to increase the dosage of the corticosteroid for a period of time consistent with the patient’s condition.

If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly. A. Administration for Local Effect Therapy with DEPO-MEDROL does not obviate the need for the conventional measures usually employed. Although this method of treatment will ameliorate symptoms, it is in no sense a cure and the hormone has no effect on the cause of the inflammation. 1.

Rheumatoid Arthritis and Osteoarthritis: The dose for intra-articular administration depends upon the size of the joint and varies with the severity of the condition in the individual patient. In chronic cases, injections may be repeated at intervals ranging from one to five or more weeks, depending upon the degree of relief obtained from the initial injection.

The doses in the following table are given as a general guide: Size of Joint Examples Range of Dosage Large Knees Ankles Shoulders 20 to 80 mg Medium Elbows Wrists 10 to 40 mg Small Metacarpophalangeal Interphalangeal Sternoclavicular Acromioclavicular 4 to 10 mg Procedure: It is recommended that the anatomy of the joint involved be reviewed before attempting intra-articular injection. To obtain the full anti‑inflammatory effect, it is important that the injection be made into the synovial space.

Employing the same sterile technique as for a lumbar puncture, a sterile 20 to 24 gauge needle (on a dry syringe) is quickly inserted into the synovial cavity. Procaine infiltration is elective. The aspiration of only a few drops of joint fluid proves the joint space has been entered by the needle. The injection site for each joint is determined by the location where the synovial cavity is most superficial and most free of large vessels and nerves.

With the needle in place, the aspirating syringe is removed and replaced by a second syringe containing the desired amount of DEPO-MEDROL. The plunger is then pulled outward slightly to aspirate synovial fluid and to make sure the needle is still in the synovial space. After injection, the joint is moved gently a few times to aid mixing of the synovial fluid and the suspension.

The site is covered with a small sterile dressing. Suitable sites for intra-articular injection are the knee, ankle, wrist, elbow, shoulder, phalangeal, and hip joints. Since difficulty is not infrequently encountered in entering the hip joint, precautions should be taken to avoid any large blood vessels in the area. Joints not suitable for injection are those that are anatomically inaccessible such as the spinal joints and those like the sacroiliac joints that are devoid of synovial space.

Treatment failures are most frequently the result of failure to enter the joint space. Little or no benefit follows injection into surrounding tissue. If failures occur when injections into the synovial spaces are certain, as determined by aspiration of fluid, repeated injections are usually futile. If a local anesthetic is used prior to injection of DEPO-MEDROL, the anesthetic package insert should be read carefully, and all the precautions observed. 2.

Bursitis: The area around the injection site is prepared in a sterile way and a wheal at the site made with 1 percent procaine hydrochloride solution. A 20 to 24 gauge needle attached to a dry syringe is inserted into the bursa and the fluid aspirated. The needle is left in place and the aspirating syringe changed for a small syringe containing the desired dose.

After injection, the needle is withdrawn and a small dressing applied. 3. Miscellaneous: Ganglion, Tendinitis, Epicondylitis: In the treatment of conditions such as tendinitis or tenosynovitis, care should be taken following application of a suitable antiseptic to the overlying skin to inject the suspension into the tendon sheath rather than into the substance of the tendon.

The tendon may be readily palpated when placed on a stretch. When treating conditions such as epicondylitis, the area of greatest tenderness should be outlined carefully and the suspension infiltrated into the area. For ganglia of the tendon sheaths, the suspension is injected directly into the cyst. In many cases, a single injection causes a marked decrease in the size of the cystic tumor and may affect disappearance.

The usual sterile precautions should be observed, of course, with each injection. The dose in the treatment of the various conditions of the tendinous or bursal structures listed above varies with the condition being treated and ranges from 4 to 30 mg. In recurrent or chronic conditions, repeated injections may be necessary. 4.

Injections for Local Effect in Dermatologic Conditions: Following cleansing with an appropriate antiseptic such as 70% alcohol, 20 to 60 mg is injected into the lesion. It may be necessary to distribute doses ranging from 20 to 40 mg by repeated local injections in the case of large lesions. Care should be taken to avoid injection of sufficient material to cause blanching since this may be followed by a small slough.

One to four injections are usually employed, the intervals between injections varying with the type of lesion being treated and the duration of improvement produced by the initial injection. B. Administration for Systemic Effect The intramuscular dosage will vary with the condition being treated. When employed as a temporary substitute for oral therapy, a single injection during each 24-hour period of a dose of the suspension equal to the total daily oral dose of MEDROL ® Tablets (methylprednisolone tablets, USP) is usually sufficient.

When a prolonged effect is desired, the weekly dose may be calculated by multiplying the daily oral dose by 7 and given as a single intramuscular injection. In pediatric patients, the initial dose of methylprednisolone may vary depending on the specific disease entity being treated. Dosage must be individualized according to the severity of the disease and response of the patient.

The recommended dosage may be reduced for pediatric patients, but dosage should be governed by the severity of the condition rather than by strict adherence to the ratio indicated by age or body weight. In patients with the adrenogenital syndrome, a single intramuscular injection of 40 mg every two weeks may be adequate.

For maintenance of patients with rheumatoid arthritis, the weekly intramuscular dose will vary from 40 to 120 mg. The usual dosage for patients with dermatologic lesions benefited by systemic corticoid therapy is 40 to 120 mg of methylprednisolone acetate administered intramuscularly at weekly intervals for one to four weeks.

In acute severe dermatitis due to poison ivy, relief may result within 8 to 12 hours following intramuscular administration of a single dose of 80 to 120 mg. In chronic contact dermatitis, repeated injections at 5 to 10 day intervals may be necessary. In seborrheic dermatitis, a weekly dose of 80 mg may be adequate to control the condition.

Following intramuscular administration of 80 to 120 mg to asthmatic patients, relief may result within 6 to 48 hours and persist for several days to two weeks. If signs of stress are associated with the condition being treated, the dosage of the suspension should be increased. If a rapid hormonal effect of maximum intensity is required, the intravenous administration of highly soluble methylprednisolone sodium succinate is indicated.

For the purpose of comparison, the following is the equivalent milligram dose of the various glucocorticoids: Cortisone, 25 Triamcinolone, 4 Hydrocortisone, 20 Paramethasone, 2 Prednisolone, 5 Betamethasone, 0.75 Prednisone, 5 Dexamethasone, 0.75 Methylprednisolone, 4 These dose relationships apply only to oral or intravenous administration of these compounds. When these substances or their derivatives are injected intramuscularly or into joint spaces, their relative properties may be greatly altered.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use The efficacy and safety of corticosteroids in the pediatric population are based on the well-established course of effect of corticosteroids which is similar in pediatric and adult populations. Published studies provide evidence of efficacy and safety in pediatric patients for the treatment of nephritic syndrome (patients >2 years of age) and aggressive lymphomas and leukemias (patients >1 month of age).

Other indications for pediatric use of corticosteroids (e.g., severe asthma and wheezing) are based on adequate and well-controlled clinical trials conducted in adults, on the premises that the course of the diseases and their pathophysiology are considered to be substantially similar in both populations. The adverse effects of corticosteroids in pediatric patients are similar to those in adults (see ADVERSE REACTIONS).

Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of infection, psychosocial disturbances, thromboembolism, peptic ulcers, cataracts, and osteoporosis. Pediatric patients who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity.

This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of HPA axis suppression (i.e., cosyntropin stimulation and basal cortisol plasma levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function.

The linear growth of pediatric patients treated with corticosteroids should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of treatment alternatives. In order to minimize the potential growth effects of corticosteroids, pediatric patients should be titrated to the lowest effective dose.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Dosage forms

Philippines

  • Tablet: 4 mg, 8 mg, 16 mg
  • Powder for injection: 1 g, 40 mg, 125 mg, 125 mg/mL, 500 mg
  • Lyophilized powder for injection: 1 g, 40 mg, 500 mg
  • Powder for solution for injection: 40 mg, 125 mg, 500 mg
  • Sterile aqueous suspension for injection: 40 mg/mL

Registered products in the Philippines

85 products registered with the Food and Drug Administration (FDA) Philippines list Methylprednisolone as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Methylprednisolone Aceponate (1 product, possible match) · Methylprednisoone ( as sodium succinate) (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products85
Philippine FDA-registered products for Methylprednisolone
Package insert
Biprosolone - 125Methylprednisolone (as Sodium Succinate)
125 mg Powder for Solution for Injection (IM/IV)USP Type I 5 mL Glass Vial with 20 mm Bromobutyl Rubber Closure and Aluminum Flip-Off Seal (Box of 1's)
Rx
Swiss Parenterals Pvt. Ltd.India
Sonchel Pharma DistributorsImporter: Ambica International CorporationTrader: BioRx Pharma Labs LLP
DRP-8713
Jan 4, 2028
Biprosolone-500Methylprednisolone (as Sodium Succinate)
500 mg Powder for Solution for Injection (IM/IV)USP Type I 10 mL Glass Vial with 20 mm Bromobutyl Rubber Closure and Aluminum Flip-Off Seal (Box of 1's)
Rx
Swiss Parenterals Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Trader: BioRx Pharma Labs LLP
DRP-8751
Jan 4, 2028
Blodis-1000Methylprednisolone (As Sodium Succinate)
1 g Lyophilized Powder for Injection (IM/IV)30 mL-capacity USP Type I clear and colorless glass vial plugged with grey bromobutyl rubber stopper and sealed with blue aluminium flip-off seal + 20 mL ed with clear and colorless glass ampoule [Sterile Water for Injection as diluent] diluent] (Box of 1's)
Rx
East African (India) OverseasIndia
Ambica International Corporation.Importer: Ambica International Corporation
DRP-13202
Dec 28, 2027
Blodis-40Methylprednisolone (As Sodium Succinate)
40 mg Lyophilized Powder for Injection (IM/IV)7.5 mL-capacity USP Type I clear and colorless glass vial plugged with grey bromobutyl rubber stopper and sealed with aluminium flip-off seal + 5 mL clear and 1 with a colorless glass ampoule [Sterile Water for Injection as diluent] (Box of of 1's)
Rx
East African (India) OverseasIndia
Ambica International Corporation.Importer: Ambica International Corporation
DRP-13203
Dec 28, 2027
Ciropred-40Methylprednisoone ( as sodium succinate)Variant spelling
40 mg Powder for Injection (IM/IV)7.5mL USP Type III Flint glass vial with grey rubber plug and flip-off aluminum seal (Box of 50's)
Rx
Ciron Drugs & Pharmaceuticals Pvt. LimitedIndia
Biocare Lifesciences Inc.
DRP-8840
Jul 2, 2030
CompredMethylprednisolone (as sodium succinate)
1 g Powder for Injection (IV)USP Type I Glass Vial + 16 mL diluent (Box of 1's)
Rx
United Biotech (P) Ltd.India
Compharm, Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-4317-04
Oct 17, 2027
CortimepMethylprednisolone (as sodium succinate)
40mg Powder For Injection (IM/IV)USP Type I glass vial (10 mL capacity) with butyl rubber stopper, aluminum seal, and green flip-off cap (Box of 1's)
Rx
BCWorld Pharm. Co., Ltd.Korea
JLT Pharma Inc.
DRP-13889
May 23, 2028
Cortisal 4Methylprednisolone
4 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
Rx
Huazhong Pharmaceutical Co. Ltd.China
Emcure Pharma Philippines, Inc.Importer: AMB HK Enterprises, Inc.
DRP-16112-01
Nov 6, 2029
Depo-MedrolMethylprednisolone acetate
40 mg/mL Sterile Aqueous Suspension for Injection (IM)USP Type I glass vial with chlorobutyl rubber stopper with aluminum seal and polypropylene flip-off cap x 1 mL (Box of 1's)
Rx
Pfizer Manufacturing Belgium NVBelgium
Pfizer, Inc.
DR-XY7140
Apr 13, 2031
Empred-40Methylprednisolone Acetate
40 mg / mL Sterile Aqueous Suspension for Injection (I.M)1 mL Suspension Filled in 2 mL Clear Glass Vial with Gray Rubber Stopper and Flip-Off Seal (Box of 1's)
Rx
Zee Laboratories LimitedHimachal Pradesh India
Eon Pharmatek Inc.
DRP-15057
Mar 16, 2032
Empred-40Methylprednisolone Acetate
40 mg/mL Sterile Aqueous Suspension for Injection (IM)1 mL Suspension Filled in 2 mL Clear Glass Vial with Gray Rubber Stopper and Flip-Off Seal (Box of 1's)
Rx
Zee Laboratories LimitedIndia
Eon Pharmatek, Inc.
DR-XY47822
Mar 16, 2027
FoscasonMethylprednisolone (as sodium succinate)
40 mg Powder for Injection (I.V./I.M.)USP Type I plain glass Vial sealed with 20 mm grey bromo butyl rubber stopper and 20 mm flip off seal (Box of 1's)
Rx
Swiss Parenterals Ltd.India
Ambica International Corporation
DRP-7469
Nov 20, 2027
ImsoloneMethylprednisolone (as Sodium Succinate)
40 mg Powder for Injection (IM/IV)USP Type I Clear and Colorless Glass Vial x 5 mL (In Individual Box)
Rx
Gufic Biosciences Ltd.India
SRS Life Sciences Inc.
DR-XY42291
Jul 29, 2028
MedcortinMethylprednisolone
16 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Healer's Lab (Unit II)India
Phoenix Pharmaceutical, Inc.Importer: Pharmakon Biotec Inc.
DRP-5412-03
Aug 4, 2029
MedixonMethylprednisolone
16 mg TabletFoil strip x 6's (Box of 30's)
Rx
PT. Dexa MedicaIndonesia
Glorious Dexa Mandaya, Inc.
DRP-1197
May 10, 2031
MedixonMethylprednisolone
4 mg TabletBlister Pack X 10's (Box of 100's)
Rx
Pt. Dexa MedicaIndonesia
Glorious Dexa Mandaya, Inc.
DRP-1153
May 3, 2031
MedpresinMethylprednisolone
16 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
Rx
Healer's Lab (Unit II)India
Cyden Medicale Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-5412
Aug 4, 2029
MedpresinMethylprednisolone
4 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
Rx
Healer's Lab. (Unit II)India
Pharmakon Biotec Inc.
DRP-5415
Aug 4, 2029
MedrolMethylprednisolone
16 mg TabletAlu/PVC/Aclar Blister Pack x 10's Box of 30's
Rx
Pfizer Talia S.R.L.Italy
Importer: Pfizer, Inc.
DRP-3441
May 10, 2027
MedrolMethylprednisolone
4 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's); Alu/Clear PVC Blister Pack x 1's - Physician's Sample (Box of 1's)
Rx
Pfizer Italia S.R.L.Italy
Pfizer Inc.
DRP-3440
May 31, 2027
MedroneMethylprednisolone (as sodium succinate)
1 g Lyophilized Powder for Injection (I.M./I.V.)30 mL-capacity USP Type I clear and colorless glass vial plugged with grey bromobutyl rubber stopper and sealed with blue aluminum flip-off seal + 20 mL clear and colorless glass ampoule [Sterile Water for Injection as diluent] (Box of 1’s)
Rx
East African (India) OverseasIndia
One Pharma Marketing Inc.Importer: Ambica International Corporation
DRP-13202-03
Dec 28, 2027
MedroneMethylprednisolone (as sodium succinate)
500 mg Lyophilized Powder for Injection (IM/IV)15 mL Capacity USP Type I Clear and Colorless Glass Vial with Grey Rubber Stopper and Green Colored Flip-off Seal + Bacteriostatic Water for Injection x 8 mL in 10 mL Capacity Clear and Colorless Glass Ampoule as Diluent (Box of 1's)
Rx
Hanlim Pharmaceutical Co., Ltd.Republic of Korea
One Pharma Marketing Inc.Importer: H & B Pharma International Inc.
DRP-6479
May 18, 2031
MepresoneMethylprednisolone
16 mg TabletFoil Strip x 6’s (Box of 30’s)
Rx
PT Dexa MedicaIndonesia
The Cathay Drug Co., Inc.Importer: Glorious Dexa Mandaya, Inc.
DRP-1197-01
May 10, 2031
MepresoneMethylprednisolone
4 mg TabletBlister Pack x 10's (Box of 100's)
Rx
PT Dexa MedicaIndonesia
The Cathay Drug Co., Inc.Importer: Glorious Dexa Mandaya, Inc.
DRP-1153-01
May 3, 2031
Mepresone 40Methylprednisolone (as sodium succinate)
40 mg Powder for Solution for Injection (IM/IV)USP Type III Clear Glass Vial x 7.5 mL (Box of 1’s)
Rx
Lyka Labs LimitedIndia
The Cathay Drug Co., Inc.Importer: Ambica International Corporation
DRP-6110-04
Apr 16, 2030
MetcortMethylprednisolone
16 mg TabletLaminated Aluminum Flex Foil x 10's (Box of 100's)
Rx
Asian Antibiotics, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY43002
Nov 22, 2028
MetcortMethylprednisolone
4 mg TabletLaminated Aluminum Flex Foil x 10's Box of 100's
Rx
Asian Antibiotics, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY42732
Oct 3, 2028
MethydenMethylprednisolone (as sodium succinate)
1 g Powder for InjectionUSP Type I Glass Vial + 16 mL diluent (Box of 1's)
Rx
United Biotech (P) Ltd.India
Cyden Medicale TradingImporter: Sanimed Pharmaceuticals Inc.
DRP-4317-01
Oct 17, 2027
MethydenMethylprednisolone
16 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Healer's Lab (Unit II)India
Cyden Medicale Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-5412-04
Aug 4, 2029
MethydenMethylprednisolone
4 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Healer's Lab. Unit IIIndia
Cyden Medicale Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-5415-03
Aug 4, 2029
Methyl-OneMethylprednisolone (as sodium succinate)
40 mg Powder for Solution for Injection (IM/IV)USP Type III Clear Glass Vial x 7.5 mL (Box of 1's)
Rx
Lyka Labs LimitedIndia
One Pharma Marketing Inc.Importer: Ambica International Corporation
DRP-6110-03
Apr 16, 2030
MethyldexMethylprednisolone (as sodium succinate)
40 mg Powder for Injection (I.V./I.M.)USP Type I plain glass Vial sealed with 20 mm grey bromo butyl rubber stopper and 20 mm flip off seal (Box of 1's)
Rx
BioRx Pharma Labs LLPIndia
Detoxicare Philippines, Inc.Importer: Ambica International Corporation
DRP-7469-02
Nov 20, 2027
MethylpredMethylprednisolone (as sodium succinate)
40 mg Powder for Solution for Injection (IM/IV)USP Type III Clear Glass Vial x 7.5 mL Box of 1's
Rx
Lyka Labs LimitedIndia
Ambica International Corporation
DRP-6110
Apr 16, 2030
MethylpredsaphMethylprednisolone
4 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
Rx
Genom Biotech Pvt. Ltd.India
Ollen Pharma Trading, Inc.
DRP-14425
Jun 17, 2031
Methyxale - 500Methylprednisolone (as Sodium Succinate)
500 mg Powder for Solution for Injection (IM/IV)USP Type I 10 mL Glass Vial with 20 mm Bromobutyl Rubber Closure and Aluminum Flip-Off Seal (Box of 1's)
Rx
Swiss Parenterals Pvt. Ltd.India
Uni-Pharma Phils., Inc.Importer: Ambicare Pharmaceuticals Inc.Trader: BioRx Pharma Labs LLP
DRP-8751-01
Jan 4, 2028
Methyxale-1000Methylprednisolone (as sodium succinate)
1g Lyophilized Powder for Injection (I.M./I.V)30 mL-capacity USP Type I clear and colorless glass vial plugged with blue aluminum flip-off seal + 20 mL clear and colorless glass ampoule [Sterile Water for Injection as diluent] (Box of 1’s)
Rx
East African (India) OverseasIndia
Uni-Pharma Phils., Inc.Importer: Ambica International Corporation
DRP-13202-01
Dec 28, 2027
Methyxale-125Methylprednisolone (as Sodium Succinate)
125 mg Powder for Solution for Injection (IM/IV)USP Type I 5 mL Glass Vial with 20 mm Bromobutyl Rubber Closure and Aluminum Flip-Off Seal (Box of 1's)
Rx
Swiss Parenterals Pvt. Ltd.India
Uni-Pharma Phils., Inc.Importer: Ambica International CorporationTrader: BioRx Pharma Labs LLP
DRP-8713-01
Jan 4, 2028
Methyxale-40Methylprednisolone (as sodium succinate)
40 mg Powder for Injection (I.V./I.M.)USP Type I plain glass Vial sealed with 20 mm grey bromo butyl rubber stopper and 20 mm flip off seal (Box of 1's)
Rx
Swiss Parenterals Ltd. (Block-B)India
Uni-Pharma Phils., Inc.Importer: Ambica International Corporation
DRP-7469-03
Nov 20, 2027
MethyxicareMethylprednisolone (as sodium succinate)
40 mg Powder for Solution for Injection (IM/IV)USP Type III Clear Glass Vial x 7.5 mL (Box of 1's)
Rx
Lyka Labs LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-6110-02
Apr 16, 2030
MetonMethylprednisolone
16 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's); Alu/Alu Blister Pack x 10's (Box of 30's)
Rx
Healer's Lab. Unit IIIndia
Alkem Laboratories CorporationImporter: Pharmakon Biotec Inc.
DRP-5412-05
Aug 4, 2029
Metprez 16Methylprednisolone
16 mg TabletAlu-Alu blister pack x 10's (Box of 30's and 100's)
Rx
Huazhong Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-16096
Oct 30, 2029
Metprez 4Methylprednisolone
4 mg TabletAlu-Alu blister pack x 10's (Box of 30's and 100's)
Rx
Huazhong Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-16112
Nov 6, 2029
MpredMethylprednisolone (as sodium succinate)
1 g Powder for Injection (I.M./I.V.)USP Type I Clear and Colorless Glass Vial (Box of 1's)
Rx
Samarth Life Sciences Pvt. Ltd. (Unit II)India
Next Chemical Enterprises
DRP-9343
Apr 3, 2027
MpredMethylprednisolone (as Sodium Succinate)
500 mg Powder for Injection (IM/IV)USP Type I Clear and Colorless Glass Vial with Violet Colored Aluminum Flip-off Seal x 20 mL (Box of 1's)
Rx
Samarth Life Science Pvt. LtdIndia
Next Chemical Enterprises
DRP-9342
Sep 30, 2031
MPSS 1000Methylprednisolone (as sodium succinate)
1 g Powder for Injection (IV)USP Type I Glass Vial + 16 mL diluent Box of 1's
Rx
United Biotech (P) Ltd.India
Importer: Sanimed Pharmaceuticals Inc.
DRP-4317
Oct 17, 2027
NoneMethylprednisolone
16 mg TabletAlu/PVC/Aclar Blister Pack x 10's Box of 30's
Rx
Pfizer Italia S.R.L.Italy
Philusa CorporationImporter: Pfizer, Inc.
DRP-3441-01
May 10, 2027
NoneMethylprednisolone
16 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Healer's Lab (Unit II)India
Reta DrugImporter: Pharmakon Biotec Inc.
DRP-5412-10
Aug 4, 2029
NoneMethylprednisolone
4 mg TabletAlu/Clear PVC Blister Pack x 10's Box of 100's
Rx
Pfizer Italia S.R.L.Italy
Philusa CorporationImporter: Pfizer, Inc.
DRP-3440-01
May 31, 2027
NoneMethylprednisolone
4 mg TabletAlu / Alu Blister Pack x 10's (Box of 100's)
Rx
Healer's Lab (Unit II)India
Reta DrugImporter: Pharmakon Biotec Inc.
DRP-5415-04
Aug 4, 2029
NovestrolMethylprednisolone Sodium Succinate
125 mg/mL Powder For Injection (IV/IM)6 mL USP Type I Glass Vial with Grey Rubber Stopper and Yellow Flip-Off Cap and 2 mL Solution for Reconstitution in Type I Glass Ampoule (Box of 1's)
Rx
PT.Novell Pharmaceutical LaboratoriesIndonesia
Prosweal Healthcare Inc.
DR-XY47850
Mar 30, 2027
Philcort-16Methylprednisolone
16 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Baroque Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-14508
Sep 15, 2028
Philcort-16Methylprednisolone
16 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-17783
Mar 11, 2031
Philcort-4Methylprednisolone
4 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Baroque Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-14509
Sep 15, 2028
PhilsolonMethylprednisolone (as sodium succinate)
40mg Lyophilized Powder For Injection (I. M./I.V.)Borosilicate vial x 3 mL with grey bromobutyl rubber stopper, aluminum seal and blue flip-off cap (Box of 10's )
Rx
Fuan Pharmaceutical Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-14086
Jun 30, 2028
Pred 8Methylprednisolone
8 mg TabletAlu/White PVC-PVdC Blister Pack x 10's (Box of 30's)
Rx
Lloyd Laboratories Inc.Philippines
Trader: Prosel Pharmaceuticals & Distributors, Inc.
DR-XY49752
Jun 15, 2031
PredhilMethylprednisolone (as sodium succinate)
1 g Powder for Injection (IV)USP Type I Glass Vial + 16 mL diluent (Box of 1's)
Rx
United Biotech (P) Ltd.India
Hillcross Prime, Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-4317-03
Oct 17, 2027
PredmetMethylprednisolone
16 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
Rx
Healer's Lab (Unit II)India
Biocare Lifesciences, Inc.Importer: Pharmakon Biotec Inc.
DRP-5412-09
Aug 4, 2029
PredmoreMethylprednisolone
16 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Healer's Lab (Unit II)India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-5412-07
Aug 4, 2029
PrednazMethylprednisolone (as sodium succinate)
1g Powder for Injection (IM/IV)20 mL Type III Clear Glass Vial Sealed with Gray Rubber Stopper and Aluminum Flip-Off Seal Cap in HIP Plastic Tray x 1's (Box of 1's)
Rx
Indasi Lifescience Pvt. Ltd.India
Aglobal Care, Inc.
DRP-13292
Jan 18, 2028
PrednicortMethylprednisolone (as sodium succinate)
1 g Powder for Injection (IM/IV)USP Type III clear glass vial with 20 mm grey butyl rubber stopper and 20 mm orange flip-off seal x 20 mL (Box of 1’s) (Box of 1’s)
Rx
Nitin Lifesciences Ltd.India
Seapharma International, Inc.
DRP-8712
Sep 27, 2029
PredniferMethylprednisolone
16 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Healer's Lab (Unit II)India
Ferma Drug EnterprisesImporter: Pharmakon Biotec, Inc.
DRP-5412-11
Aug 4, 2029
Prednivex 16Methylprednisolone
16 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
West Coast Pharmaceutical Works. LtdIndia
VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd
DR-XY44853
Oct 5, 2030
Prednivex 4Methylprednisolone
4 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
West Coast Pharmaceutical Works. LtdIndia
VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd
DR-XY44854
Oct 5, 2030
Prednox-16Methylprednisolone
16 mg TabletAluminum Foil Strip x 10's (Box of 50's)
Rx
PT PYRIDAM FARMA TBKIndonesia
One Pharma Marketing Inc.
DRP-5537
Jun 11, 2031
PredsanMethylprednisolone (as sodium succinate)
1 g Powder for Injection (IV)USP Type I Glass Vial + 16 mL Diluent (Box of 1's)
Rx
United Biotech (P) Ltd.India
Hillcross Prime, IncImporter: Sanimed Pharmaceuticals Inc.
DRP-4317-02
Oct 17, 2027
PredsarMethylprednisolone
16 mg TabletAlu/Alu Blister Pack x 10's Box of 100's
Rx
Healer's Lab (Unit II)India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-5412-06
Aug 4, 2029
PredsenzMethylprednisolone (as sodium succinate)
500 mg Lyophilized Powder for Injection (IM/IV)15 mL Capacity USP Type I Clear and Colorless Glass Vial with Grey Rubber Stopper and Green Colored Flip-off Seal + 8 mL in 10 mL Capacity Clear and Colorless Glass Ampoule with Bacteriostatic Water for Injection as diluent Box of 1's
Rx
Hanlim Pharmaceutical Co., Ltd.Republic of Korea
Pharmaessence Inc.Importer: H & B Pharma International Inc.
DRP-6479-01
Jan 19, 2032
PredylMethylprednisolone (as sodium succinate)
40 mg Lyophilized Powder for Injection (I.V./I.M.)USP Type I Clear glass vial stoppered with grey-colored chlorobutyl rubber stoppers and sealed with orange flip-off (Box of 10's)
Rx
Myungmoon Pharmaceutical Co., Ltd.Republic of Korea
Central West Medicale Inc.Importer: H & B Pharma International Inc.
DRP-5807
Nov 17, 2029
Predyl 1000Methylprednisolone (as sodium succinate)
1g Lyophilized Powder for Injection (I.M./I.V.)30 mL-capacity USP Type I clear and colorless glass vial plugged with grey bromobutyl rubber stopper and sealed with blue aluminum flip-off seal + 20 mL clear and colorless glass ampoule [Sterile Water for Injection as diluent] (Box of 1’s)
Rx
East African (India) OverseasIndia
Central West Medicale Inc.Importer: Ambica International Corporation
DRP-13202-02
Dec 28, 2027
Predyl 40Methylprednisolone (as sodium succinate)
40 mg Lyophilized Powder for Injection (I.M./I.V.)7.5 mL - capacity USP Type I clear and colorless glass vial plugged with grey bromobutyl rubber stopper and sealed with aluminium flip-off seal + 5 mL clear and colorless glass ampoule [Sterile Water for Injection as diluent] (Box of 1’s)
Rx
East African (India) OverseasIndia
Central West Medicale Inc.Importer: Ambica International Corporation
DRP-13203-01
Dec 28, 2027
Solu-MedrolMethylprednisolone (as Sodium Succinate)
125 mg Powder for Injection (IM/IV)2 mL Act-O-Vial (Box of 1’s)
Rx
Pharmacia & Upjohn CompanyUSA
Importer: Pfizer, Inc.
DRP-2128
Dec 10, 2029
Solu-MedrolMethylprednisolone (as sodium succinate)
1g Powder for Injection (IM/IV)Colorless glass vial + vial of solvent per box
Rx
Pfizer Manufacturing Belgium NVBelgium
Importer: Pfizer, Inc.
DRP-2155
Jul 29, 2027
Solu-MedrolMethylprednisolone sodium succinate
40 mg Lyophilized Powder for Injection (IM/IV)Hydrolytic Type I Clear Glass Act-O-Vial (Lyophilized Powder in the lower compartment and diluent in the upper compartment) (Box of 1’s)
Rx
Pfizer Manufacturing Belgium NVBelgium
Importer: Pfizer, Inc.
DRP-2156
Oct 8, 2029
Solu-MedrolMethylprednisolone (as sodium succinate)
40 mg Lyophilized Powder for Injection (IM/IV)USP Type I clear and colorless glass Act-O-Vial™ x 1 mL with 2 compartments for both the freeze-dried product (lower) and Water for Injection as diluent (upper) separated by a sterile halobutyl rubber center plug with a sterile top halobutyl plunger secured by a white opaque HDPE activator cap (Box of 1's)
Rx
Pharmacia & Upjohn Company LLCUSA
Importer: Pfizer, Inc.Trader: Pfizer, Inc.
DRP-7404
Oct 18, 2027
Solu-MedrolMethylprednisolone (as sodium succinate)
500 mg Powder for Injection (I.M./I.V.)Type I Glass Vial (containing drug) and 8 mL Water for Injection (as diluent) in separate Vial (Box of 1's)
Rx
Pharmacia & Upjohn Company LLCUSA
Importer: Pfizer, Inc.
DRP-2157
Jan 20, 2027
Solu-pedMethylprednisolone (as Sodium Succinate)
500 mg Powder for InjectionGlass vial with rubber stopper and green flip off seal + Diluents (Bacteriostatic Water for Injection USP) per box
Rx
Huons Co., LtdKorea
Endure Medical, Inc.
DR-XY31968
Sep 26, 2029
SuccimedMethylprednisolone Sodium Succinate
1 g Powder For Injection (IV/IM)20 mL USP Type III Vial with Grey Butyl Rubber Plug and Aluminum Flip-Off Seal (Box of 1's)
Rx
VHB Medi Sciences LimitedIndia
Brady Pharma Inc.
DR-XY47852
Mar 30, 2027
TilosoneMethylprednisolone
16 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
Rx
Huazhong Pharmaceutical Co., Ltd.China
Emcure Pharma Philippines, Inc.Importer: AMB HK Enterprises, Inc.
DRP-16096-01
Oct 30, 2029
TrimesoloneMethylprednisolone (as sodium succinate)
1 g Powder for Injection (I.M./I.V.)USP Type I Clear and Colorless Glass Vial (Box of 1's)
Rx
Samarth Life Sciences Pvt. Ltd. (Unit II)India
Triple Tact Import & Export Corp.Importer: Next Chemical Enterprises
DRP-9343-01
Apr 3, 2027
Zelpred-KMethylprednisolone
16 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Healer's Lab (Unit II)India
Kodapharm Med Corp.Importer: Pharmakon Biotec Inc.
DRP-5412-08
Aug 4, 2029
Zelpred-KMethylprednisolone
4 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Healer's Lab (Unit II)India
Kodapharm Med CorpImporter: Pharmakon Biotec Inc.
DRP-5415-02
Aug 4, 2029
(no brand name)Methylprednisolone
16 mg TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
—
DRP-18115
May 6, 2031
(no brand name)Methylprednisolone
4 mg TabletAlu/White PVC-PVdC Blister Pack x 10's (Box of 30's)
Rx
Lloyd Laboratories Inc.Philippines
—
DRP-18345
Jun 17, 2031
(no brand name)Methylprednisolone (as sodium succinate)
40mg Powder for Injection (IM/IV)Type I Glass Vial Sealed with Rubber Stopper and Aluminum Flip-Off Cap x l's (Box of 1’s and 10's)
Rx
Gentle Pharma Co., Ltd.Taiwan
Importer: Kwanstar Pharma Distributor
DRP-12051
Jun 3, 2027
(no brand name)Methylprednisolone
8 mg TabletAlu/Clear PVC-PVdC Blister Pack x 10's (Box of 30's)
Rx
Lloyd Laboratories Inc.Philippines
—
DR-XY49751
Jun 15, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS Serious Neurologic Adverse Reactions with Epidural Administration Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke.

These serious neurologic events have been reported with and without use of fluoroscopy. The safety and effectiveness of epidural administration of corticosteroids have not been established, and corticosteroids are not approved for this use. General This product is not suitable for multi-dose use. Following administration of the desired dose, any remaining suspension should be discarded.

Injection of DEPO-MEDROL may result in dermal and/or subdermal changes forming depressions in the skin at the injection site. In order to minimize the incidence of dermal and subdermal atrophy, care must be exercised not to exceed recommended doses in injections. Multiple small injections into the area of the lesion should be made whenever possible.

The technique of intra-articular and intramuscular injection should include precautions against injection or leakage into the dermis. Injection into the deltoid muscle should be avoided because of a high incidence of subcutaneous atrophy. It is critical that, during administration of DEPO-MEDROL, appropriate technique be used and care taken to ensure proper placement of drug.

Rare instances of anaphylactoid reactions have occurred in patients receiving corticosteroid therapy (see ADVERSE REACTIONS). Increased dosage of rapidly acting corticosteroids is indicated in patients on corticosteroid therapy subjected to any unusual stress before, during, and after the stressful situation. Results from one multicenter, randomized, placebo-controlled study with methylprednisolone hemisuccinate, an IV corticosteroid, showed an increase in early (at 2 weeks) and late (at 6 months) mortality in patients with cranial trauma who were determined not to have other clear indications for corticosteroid treatment.

High doses of systemic corticosteroids, including DEPO-MEDROL, should not be used for the treatment of traumatic brain injury. Cardio-renal Average and large doses of corticosteroids can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with synthetic derivatives when used in large doses.

Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with corticosteroids should be used with great caution in these patients.

There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure (see CONTRAINDICATIONS and PRECAUTIONS: Drug Interactions, Amphotericin B injection and potassium-depleting agents). Endocrine Hypothalamic-pituitary adrenal (HPA) axis suppression.

Cushing's syndrome, and Hyperglycemia: monitor patients for these conditions with chronic use. Corticosteroids can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Drug induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage.

This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Immunosuppression and Increased Risk of Infection Corticosteroids, including DEPO-MEDROL, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens.

Corticosteroids can: Reduce resistance to new infections Exacerbate existing infections Increase the risk of disseminated infections Increase the risk of reactivation or exacerbation of latent infections Mask some signs of infection Corticosteroid-associated infections can be mild but can be severe and at times fatal. The rate of infectious complications increases with increasing corticosteroid dosages.

Monitor for the development of infection and consider DEPO-MEDROL withdrawal or dosage reduction as needed. Do not administer DEPO-MEDROL by an intraarticular, intrabursal, intratendinous or intralesional route in the presence of acute local infection. Tuberculosis: If DEPO-MEDROL is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, as reactivation of the disease may occur.

Closely monitor such patients for reactivation. During prolonged DEPO-MEDROL therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis. Varicella Zoster and Measles Viral Infections: Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including DEPO-MEDROL.

In corticosteroid‑treated patients who have not had these diseases or are non-immune, particular care should be taken to avoid exposure to varicella and measles: If a DEPO-MEDROL-treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If varicella develops, treatment with antiviral agents may be considered.

If a DEPO-MEDROL-treated patient is exposed to measles, prophylaxis with immunoglobulin (IG) may be indicated. Hepatitis B Virus Reactivation: Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including DEPO‑MEDROL. Reactivation can also occur infrequently in corticosteroid‑treated patients who appear to have resolved hepatitis B infection.

Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with DEPO-MEDROL. For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy.

Fungal Infections: Corticosteroids, including DEPO-MEDROL, may exacerbate systemic fungal infections; therefore, avoid DEPO-MEDROL use in the presence of such infections unless DEPO-MEDROL is needed to control drug reactions. For patients on chronic DEPO-MEDROL therapy who develop systemic fungal infections, DEPO-MEDROL withdrawal or dosage reduction is recommended.

Amebiasis: Corticosteroids, including DEPO-MEDROL, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating DEPO-MEDROL in patients who have spent time in the tropics or patients with unexplained diarrhea. Strongyloides Infestation: Corticosteroids, including DEPO-MEDROL, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation.

In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia. Cerebral Malaria: Avoid corticosteroids, including DEPO-MEDROL, in patients with cerebral malaria.

Vaccinations Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered. However, the response to such vaccines cannot be predicted. Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy (e.g., for Addison’s disease).

Ophthalmic Use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. The use of systemic corticosteroids is not recommended in the treatment of optic neuritis and may lead to an increase in the risk of new episodes.

Corticosteroids should be used cautiously in patients with ocular herpes simplex because of corneal perforation. Corticosteroids should not be used in active ocular herpes simplex. Kaposi’s Sarcoma Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions.

Discontinuation of corticosteroids may result in clinical improvement of Kaposi’s sarcoma.

Drug interactions

Drug interactions (US label) US FDA label

Drug Interactions Aminoglutethimide: Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression. Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.

There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see PRECAUTIONS: Drug Interactions, Hepatic Enzyme Inhibitors).

Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Anticoagulants, oral: Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.

Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. Antidiabetics: Because corticosteroids may increase blood glucose concentration, dosage adjustments of antidiabetic agents may be required. Antitubercular drugs: Serum concentrations of isoniazid may be decreased. Cholestyramine: Cholestyramine may increase the clearance of oral corticosteroids.

Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Digitalis glycosides: Patients on digitalis glycosides may be at risk of arrhythmias due to hypokalemia. Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.

Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin): Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids.

Ketoconazole: Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects. Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.

Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Skin tests: Corticosteroids may suppress reactions to skin tests. Vaccines: Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.

Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see WARNINGS: Immunosuppression and Increased Risk of Infection, Vaccinations).

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS The following adverse reactions have been reported with DEPO-MEDROL or other corticosteroids: Allergic reactions: Allergic or hypersensitivity reactions, anaphylactoid reaction, anaphylaxis, angioedema. Blood and lymphatic system disorders: Leukocytosis. Cardiovascular: Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction (see WARNINGS), pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis.

Dermatologic: Acne, allergic dermatitis, cutaneous and subcutaneous atrophy, dry scaly skin, ecchymoses and petechiae, edema, erythema, hyperpigmentation, hypopigmentation, impaired wound healing, increased sweating, rash, sterile abscess, striae, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria. Endocrine: Decreased carbohydrate and glucose tolerance, development of cushingoid state, glycosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetes, manifestations of latent diabetes mellitus, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery, or illness), suppression of growth in pediatric patients.

Fluid and electrolyte disturbances: Congestive heart failure in susceptible patients, fluid retention, hypokalemic alkalosis, potassium loss, sodium retention. Gastrointestinal: Abdominal distention, bowel/bladder dysfunction (after intrathecal administration), elevation in serum liver enzyme levels (usually reversible upon discontinuation), hepatomegaly, increased appetite, nausea, pancreatitis, peptic ulcer with possible subsequent perforation and hemorrhage, perforation of the small and large intestine (particularly in patients with inflammatory bowel disease), ulcerative esophagitis.

Metabolic: Negative nitrogen balance due to protein catabolism. Musculoskeletal: Aseptic necrosis of femoral and humeral heads, calcinosis (following intra-articular or intra-lesional use), Charcot-like arthropathy, loss of muscle mass, muscle weakness, osteoporosis, pathologic fracture of long bones, post injection flare (following intra-articular, soft tissue, and tendon sheath injections), steroid myopathy, tendon rupture, vertebral compression fractures.

Neurologic/Psychiatric: Convulsions, depression, emotional instability, euphoria, headache, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, insomnia, mood swings, neuritis, neuropathy, paresthesia, personality changes, psychic disorders, vertigo. Ophthalmic: Exophthalmoses, glaucoma, increased intraocular pressure, posterior subcapsular cataracts.

Vascular: Flushing. Other: Abnormal fat deposits, decreased resistance to infection, hiccups, increased or decreased motility and number of spermatozoa, injection site infections following non-sterile administration (see WARNINGS), malaise, moon face, weight gain. The following adverse reactions have been reported with the following routes of administration: Intrathecal/Epidural: Arachnoiditis, bowel/bladder dysfunction, headache, meningitis, parapareisis/paraplegia, seizures, sensory disturbances.

Intranasal: Allergic reactions, rhinitis, temporary/permanent visual impairment including blindness. Ophthalmic: Increased intraocular pressure, infection, ocular and periocular inflammation including allergic reactions, residue or slough at injection site, temporary/permanent visual impairment including blindness. Miscellaneous injection sites (scalp, tonsillar fauces, sphenopalatine ganglion): Blindness.

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy: Teratogenic Effects Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. Animal studies in which corticosteroids have been given to pregnant mice, rats, and rabbits have yielded an increased incidence of cleft palate in the offspring. There are no adequate and well-controlled studies in pregnant women.

Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from corticosteroids, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pharmacokinetics

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt retaining properties, are used in replacement therapy in adrenocortical deficiency states. Their synthetic analogs are used primarily for their anti-inflammatory effects in disorders of many organ systems.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Methylprednisolone 1 g/16 mL + Diluent Vial₱2,100.00–₱3,162.50Reference ₱2,100.00per vialDPRI procurement range
Methylprednisolone 4 mg Tablet₱4.15–₱14.00Reference ₱5.00per tabletDPRI procurement range
Methylprednisolone 16 mg Tablet₱6.85–₱25.30Reference ₱8.20per tabletDPRI procurement range
Methylprednisolone 40 mg ( single dose) Vial₱280.00–₱668.90Reference ₱289.95per vialDPRI procurement range
Methylprednisolone 125 mg/mL, 2 mL + diluent Vial₱597.00–₱615.00Reference ₱597.00per vialDPRI procurement range
Methylprednisolone 500 mg lyophilized powder Vial₱1,155.00–₱1,256.00Reference ₱1,155.00per vialDPRI procurement range
Methylprednisolone 500 mg/8.0 mL + diluent vial Vial₱1,161.00–₱1,250.00Reference ₱1,161.00per vialDPRI procurement range
Methylprednisolone 500mg/7.7mL + Diluent Vial₱1,200.00–₱2,280.00Reference ₱1,200.00per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Methylprednisolone
PNF listingOral: 4 mg and 16 mg tablet
PNF listingInj.: powder, 125 mg/mL, 2 mL vial + diluent vial (IM, IV, IV infusion) (as sodium succinate)
PNF listingInj.: 40 mg in single dose vial, solution for injection (IV, IM) (as sodium succinate)
PNF listingInj.: powder, 500 mg, 7.7 mL vial (IV) + diluent vial (IM, IV, IV infusion) (as sodium succinate)
PNF listingInj.: powder, 1 g/16 mL vial + diluent vial (IM, IV, IV
PNF listingInj.: infusion) (as sodium succinate)
PNF listingInj.: lyophilized powder, 125 mg vial (IM, IV) (as sodium
PNF listingInj.: succinate)
PNF listingInj.: lyophilized powder, 500 mg vial (IM, IV) (as sodium
PNF listingInj.: succinate)
PNF listingInj.: lyophilized powder, 1 g vial (IM, IV) (as sodium
PNF listingInj.: succinate)
PNF listingInj.: powder, 500 mg/8.0 mL vial + diluent vial (IM, IV, IV
PNF listingInj.: infusion) (as sodium succinate)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Depo-Medrol · Sportpharm LLC [US FDA-approved label, version 1, October 27, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95ec0e75-6b5d-4320-8f23-3d6229216ca8
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .